As interest in immunotherapy grows, so does the need for better tools to engineer CAR T cells. Could advances in CRISPR technology be the solution? In the last decade, a new immunotherapy tool has ...

Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational new drug (IND) application to begin ...

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

CRISPR technology enables targeted insertion of transgenes at the desired locus and has the ability to multiplex knocking out of multiple genes. These features provide a great opportunity to use this ...

CAR T-cell therapy process via National Cancer Institute ... The T-cells are sent off to a CRISPR lab, where they get injected with a modified, inactive virus that introduces a new gene which ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

In particular, CRISPR is being used to develop chimeric antigen receptor (CAR) T-cell therapies where immune cells are genetically engineered to attack specific tumors. In addition, some companies ...

For instance, this location could be a tumor site where CRISPR needs to be used to modify the DNA of cancer cells to make them more susceptible to attack from CAR T-cell-based immunotherapy.

Moreover, Crispr Therapeutics has reported encouraging initial clinical data from its Phase I/II trial of CTX112, an allogeneic CAR-T therapy for CD19-positive B-cell malignancies, highlighting ...

Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...